The American Heart Association, the American College of Cardiology, and the Heart Failure Society of America issued a joint statement that renin-angiotensin-aldosterone system antagonists, such as ACEi and ARBs, should be continued as prescribed for patients with COVID-19 (Bozkurt et al., 2020). Here, REN is linked to COVID-19.